超高b值DWI在遗传性平滑肌瘤病和肾细胞癌影像中的应用
本研究比较了超高b值DWI(b=2000 s/mm²)与标准DWI(b=800 s/mm²)在HLRCC患者中鉴别肾脏良恶性病变的能力。
要点
- 超高b值DWI(b=2000)可提高有经验医生对HLRCC相关肾脏病变良恶性鉴别能力。
- 低经验医生使用b=2000序列未见鉴别能力提升。
- 建议将b=2000 DWI纳入现有肾脏MRI协议。
英文原文(摘要)· 点击展开
PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is associated with an aggressive form of renal cell carcinoma with high risk of metastasis, even in small primary tumors with unequivocal imaging findings. In this study, we compare the performance of ultra-high b-value diffusion-weighted imaging (DWI) sequence (b = 2000 s/mm2) to standard DWI (b = 800 s/mm2) sequence in identifying malignant lesions in patients with HLRCC.
METHODS: Twenty-eight patients (n = 18 HLRCC patients with 22 lesions, n = 10 controls) were independently evaluated by three abdominal radiologists with different levels of experience using four combinations of MRI sequences in two separate sessions (session 1: DWI with b-800, session 2: DWI with b-2000). T1 precontrast, T2-weighted (T2WI), and apparent diffusion coefficient (ADC) sequences were similar in both sessions. Each identified lesion was subjectively assessed using a six-point cancer likelihood score based on individual sequences and overall impression.
RESULTS: The ability to distinguish benign versus malignant renal lesions improved with the use of b-2000 for more experienced radiologists (Reader 1 AUC: Session 1-0.649 and Session 2-0.938, p = 0.017; Reader 2 AUC: Session 1-0.781 and Session 2-0.921, p = 0.157); whereas no improvement was observed for the less experienced reader (AUC: Session 1-0.541 and Session 2-0.607, p = 0.699).
CONCLUSION: The inclusion of ultra-high b-value DWI sequence improved the ability of classification of renal lesions in patients with HLRCC for experienced radiologists. Consideration should be given toward incorporation of DWI with b-2000 s/mm2 into existing renal MRI protocols.
引用
- Chaurasia, Gopal, Dehghani Firouzabadi, et al. Role of ultra-high b-value DWI in the imaging of hereditary leiomyomatosis and renal cell carcinoma (HLRCC). Abdom Radiol (NY). 2022. PMID: 36207629. doi:10.1007/s00261-022-03689-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。